Latest Patents News

Page 4 of 104
Sentinel Metals has completed its first 15-hole Columbia drilling program, with fire assays confirming a broad high-grade intercept and extending mineralisation beyond the existing pit shell. The company will now turn to a November Mineral Resource update while advancing its newly acquired 1.01Moz Big Springs project in Nevada.
Maxwell Dee
Maxwell Dee
29 Oct 2026
ION Video has moved its video technology into a series of externally funded and independently assessed validation programs, including an AWS proof of concept and a potential Nordic data centre trial worth at least A$1 million. The company ended September with A$3.522 million in cash, but remains pre-revenue and expects higher spending as commercialisation efforts expand.
Sophie Babbage
Sophie Babbage
29 Oct 2026
Andromeda Metals has lifted independently verified high-purity alumina output to 99.9989% at its continuous pilot plant and sent its first commercial sample to a potential Japanese customer. The result strengthens the technical case for its HPA project, but customer qualification and commercial-scale production remain ahead.
Victor Sage
Victor Sage
29 Oct 2026
Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.
Ada Torres
Ada Torres
29 Oct 2026
Reward Minerals has completed its maiden drilling program at the Jackpot gold-copper prospect, but the more immediate investor issue is funding: the company held $262,000 in cash at 30 September, equivalent to 0.43 quarters of reported outgoings. Reward says it intends to pursue a placement or entitlement issue while awaiting assay results and continuing Beyondie partnership talks.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Ocean Sciences has committed A$100,000 to a 12-month research program testing whether Sargassum-derived alginate can recover gold, silver and potentially rare earth elements from retired data centre hardware. The project gives the seaweed company a new industrial angle, but remains firmly at the laboratory stage.
Victor Sage
Victor Sage
28 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Perpetual Resources has expanded its Nevada Scheelite tungsten project more than 15-fold and reported selective underground samples grading up to 12.03% WO₃. The exploration momentum comes with a sharper funding question, with A$1.639 million in cash and an estimated 2.37 quarters of funding at 30 September.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Andromeda Metals has produced 99.9986% purity High Purity Alumina at continuous pilot scale and raised A$3.04 million to advance its next study. But the Great White Project still needs about A$40 million in equity before a final investment decision.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Singular Health has moved closer to a proposed A$3.5 million Florida Medicaid imaging repository while deploying 1,000 physician licences through its largest customer network. The September quarter also exposed the execution risks ahead, with the Florida MOU still subject to definitive agreements and the PNS contract due for renewal by year-end.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive